BRIEF-Enanta Pharmaceuticals Q3 Revenue USD 14.359 Million Vs. IBES Estimate USD 16.8 Million
Reuters2026/08/10 20:02Aug 10 (Reuters) - Enanta Pharmaceuticals Q3 net income USD -19.501 million.
- Q3 operating expenses USD 31.595 million
- Q3 pretax profit USD -19.465 million
- Q3 operating income USD -17.236 million
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Peter Schiff reiterates the MSTR death spiral theory, claims bitcoin rebound is only temporary
Boliden plans to acquire a 64.7% stake in Nexa Resources (NEXA.US) for $1.31 billion, advancing into the Latin American mining sector.
Boliden AB has signed a final agreement with Votorantim to acquire all of Votorantim's shares in Nexa Resources, thereby obtaining approximately 64.68% of the majority voting rights of this Latin American zinc and silver producer.
Westgold declares FY26 fully franked dividend of 10 cents per share
Crypto prices
More
